This content is machine translated Type 2 diabetes ESC recommendations for reducing cardiovascular risk Patients with type 2 diabetes have a greatly increased risk of developing cardiovascular disease compared to healthy people in the same age group. The current guidelines published in the European…
View Post 9 min This content is machine translated Type 2 diabetes Updated SGED treatment recommendations published In recent years, the therapeutic landscape for type 2 diabetes has changed significantly. Because GLP-1 receptor agonists and SGLT-2 inhibitors have shown direct effects on cardiorenal protection in cardiovascular endpoint…
View Post 5 min This content is machine translated Type 2 diabetes Prevention of macrovascular complications – an update. Reducing the risk of microvascular and macrovascular sequelae is an important treatment goal in diabetes. In recent years, new modern drugs have entered the market that have demonstrated additional benefits…
View Post 4 min This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of…
